Rakela J, Goldschmiedt M, Ludwig J
Division of Gastroenterology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.
Dig Dis Sci. 1987 Dec;32(12):1358-62. doi: 10.1007/BF01296661.
A review of 19 adult patients with alpha-1-antitrypsin deficiency (A1AT deficiency) and chronic liver disease revealed a late onset of symptomatic hepatic abnormalities in this condition. Thirteen patients (68%) were 60 years or older when the liver disease was discovered. The mean age of the patients with the ZZ, SZ, and MZ phenotypes was 58, 66, and 72.5 years, respectively; this suggested a later onset of the liver disease in the heterozygotes. At the time of diagnosis, the hepatic condition usually was advanced; in eight patients (42%) the survival was less than two years. The most important associated condition was chronic obstructive lung disease which was found in 10 patients (53%). We conclude that advanced age and the high incidence of obstructive lung disease make it unlikely that liver transplantation will become a common therapeutic option for adult patients with A1AT deficiency and associated liver disease. Periodic screening of liver function may be indicated in patients with A1AT deficiency so that chronic liver disease can be diagnosed early, particularly if current attempts to develop effective medical therapy for this condition are successful.
一项针对19例α1-抗胰蛋白酶缺乏症(A1AT缺乏症)合并慢性肝病的成年患者的回顾性研究显示,在此病症中,有症状的肝脏异常发病较晚。13例患者(68%)在肝病被发现时年龄已达60岁或以上。ZZ、SZ和MZ表型患者的平均年龄分别为58岁、66岁和72.5岁;这表明杂合子中肝病发病较晚。在诊断时,肝脏病情通常已进展;8例患者(42%)生存期不足两年。最重要的相关病症是慢性阻塞性肺疾病,10例患者(53%)患有此病。我们得出结论,高龄以及阻塞性肺疾病的高发病率使得肝移植不太可能成为患有A1AT缺乏症及相关肝病的成年患者的常见治疗选择。对于A1AT缺乏症患者,可能需要定期进行肝功能筛查,以便能早期诊断慢性肝病,特别是如果目前针对该病症开发有效药物治疗的尝试取得成功的话。